<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21738">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01963312</url>
  </required_header>
  <id_info>
    <org_study_id>FMSECUR-11</org_study_id>
    <secondary_id>2011-002108-34</secondary_id>
    <nct_id>NCT01963312</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy and Safety of the Transarterial Supraselective Embolization of the Prostate to Treat the Urinary Symptoms.</brief_title>
  <official_title>A Randomised Clinical Trial to Compare Efficacy and Safety of the Transarterial Supraselective Embolization of the Prostate Compared Versus the Transurethral Resection of the Prostate to Treat the Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Miguel Servet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Miguel Servet</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the transarterial supraselective
      embolization (TSE) is a technique as effective as transurethral resection of the prostate
      (TURP) for the treatment of lower urinary tract symptoms associated with benign prostatic
      hyperplasia (BPH).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum urinary flow (Qmax)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum urinary flow (Qmax) measured prior intervention and one year later</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>International Prostate Symptom Score (IPSS) measured before and after the intervention</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in prostate volume</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual function</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed by International Index of Erectile Function (IIEF) prior and and one year after intervention.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Transurethral Resection of Prostate</condition>
  <condition>Artery Embolization</condition>
  <condition>Benign Prostatic Hyperplasia</condition>
  <condition>Lower Urinary Tract Symptoms</condition>
  <arm_group>
    <arm_group_label>Transarterial Supraselective Embolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transarterial supraselective embolization of prostatic arteria with Bead Block 300-500 μm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transurethral Resection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgery to remove part of the prostate gland</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transarterial Supraselective Embolization of the prostate</intervention_name>
    <arm_group_label>Transarterial Supraselective Embolization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transurethral Resection of the prostate</intervention_name>
    <arm_group_label>Transurethral Resection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of benign prostatic hyperplasia with moderate or severe obstructive lower
             urinary tract symptoms

          -  Refractory to medical treatment for at least 6 months

          -  Qmax (maximum urinary flow) less than 10 mL/second

        Exclusion Criteria:

          -  Advanced atherosclerosis and tortuosity of the iliac arteries

          -  No visualization of the prostatic artery CT angiography study

          -  Urethral stenosis, detrusor failure or neurogenic bladder

          -  Glomerular filtration &lt; 30 mL/min

          -  Presence of malignant tumor

          -  History of allergy to iodinated contrast
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saturnino Napal, MD</last_name>
    <role>Study Director</role>
    <affiliation>Complejo Hospitalario de Navarra</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saturnino Napal, MD</last_name>
    <phone>+34 848422385</phone>
    <email>saturnino.napal.lecumberri@cfnavarra.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarre</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferran Capdevila, PharmD</last_name>
      <phone>+34 848422163</phone>
      <email>fcapdevb@navarra.es</email>
    </contact>
    <investigator>
      <last_name>Saturnino Napal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fermin Urtasun, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iñigo Insausti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.navarrabiomed.es</url>
  </link>
  <reference>
    <citation>DeMeritt JS, Elmasri FF, Esposito MP, Rosenberg GS. Relief of benign prostatic hyperplasia-related bladder outlet obstruction after transarterial polyvinyl alcohol prostate embolization. J Vasc Interv Radiol. 2000 Jun;11(6):767-70.</citation>
    <PMID>10877424</PMID>
  </reference>
  <reference>
    <citation>Carnevale FC, Antunes AA, da Motta Leal Filho JM, de Oliveira Cerri LM, Baroni RH, Marcelino AS, Freire GC, Moreira AM, Srougi M, Cerri GG. Prostatic artery embolization as a primary treatment for benign prostatic hyperplasia: preliminary results in two patients. Cardiovasc Intervent Radiol. 2010 Apr;33(2):355-61. doi: 10.1007/s00270-009-9727-z. Epub 2009 Nov 12.</citation>
    <PMID>19908092</PMID>
  </reference>
  <reference>
    <citation>Pisco J, Campos Pinheiro L, Bilhim T, Duarte M, Rio Tinto H, Fernandes L, Vaz Santos V, Oliveira AG. Prostatic arterial embolization for benign prostatic hyperplasia: short- and intermediate-term results. Radiology. 2013 Feb;266(2):668-77. doi: 10.1148/radiol.12111601. Epub 2012 Nov 30.</citation>
    <PMID>23204546</PMID>
  </reference>
  <reference>
    <citation>Mauro MA. Can hyperplastic prostate follow uterine fibroids and be managed with transcatheter arterial embolization? Radiology. 2008 Mar;246(3):657-8. doi: 10.1148/radiol.2463071721.</citation>
    <PMID>18309010</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>March 11, 2014</lastchanged_date>
  <firstreceived_date>October 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
